Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642904 | 0.79 | HTT (0.50) | RIPK1ALOX5TRPM8HTTKDM4E | |
| SCHEMBL2806112 | 0.79 | HTT (0.50) | RIPK1ALOX5TRPM8HTTKDM4E | |
| Ammonia Solution, Strong SCHEMBL23877941 | 0.78 | HTT (0.49) | RIPK1ALOX5TRPM8HTTKDM4E | |
| SCHEMBL10241255 | 0.78 | RIPK1 (0.50) | RIPK1ALOX5TRPM8HTTKDM4E | |
| SCHEMBL733240 | 0.74 | — | — | |
| SCHEMBL28948440 | 0.74 | KDM4E (0.51) | RIPK1ALOX5HTTKDM4EPOLB | |
| SCHEMBL6952454 | 0.73 | KDM4E (0.56) | RIPK1ALOX5HTTKDM4EPOLB | |
| SCHEMBL8279945 | 0.72 | TRPM8 (0.51) | RIPK1ALOX5TRPM8POLBMAPT | |
| SCHEMBL8634675 | 0.72 | TSHR (0.56) | RIPK1ALOX5HTTKDM4EPOLB | |
| SCHEMBL5931188 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239858-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239858-A1 | THERAPEUTIC AMIDES | ACER2, SLC10A1, ASAH2 | RIPK1 4867/4885ALOX5 170/4885TRPM8 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.